Literature DB >> 22644107

Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Kazuki Murakami1, Chiaki Suzuki, Fujio Kobayashi, Atsushi Nakano, Akihiro Fujii, Kaoru Sakai, Teruaki Imada.   

Abstract

Intravenous immunoglobulin (IVIG) has been used for the treatment of inflammatory and autoimmune diseases. The ability to modulate cytokine production has been formerly described as one of the mechanisms of its action. This study aimed to investigate the effect of IVIG on the production of pro-inflammatory cytokines in lipopolysaccharide (LPS)-stimulated monocytic cells. Peripheral blood mononuclear cells (PBMCs) or THP-1 cells treated with phorbol myristate acetate (PMA) were stimulated with LPS. The protein levels of pro-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6, and high-mobility group box 1 (HMGB1)] in the culture supernatants were determined using appropriate enzyme-linked immunosorbent assay kits. The mRNA of TNF-α was determined by reverse transcription-polymerase chain reaction. The phosphorylation of nuclear factor kappa B (NF-κB) and the mitogen-activated protein kinases was examined by Western blot analyses. IVIG suppressed the production of pro-inflammatory cytokines such as TNF-α and IL-6 in LPS-stimulated PBMCs. Furthermore, IVIG inhibited TNF-α, IL-6, and HMGB1 production from LPS-stimulated THP-1 cells treated with PMA. In addition, Fc fragment prepared from the IVIG inhibited production of these cytokines from the cells to the same degree as IVIG, whereas Fab and F(ab')(2) fragments inhibited this only partially. We showed that IVIG and Fc fragments suppressed LPS-induced signal transduction pathways involving phosphorylation of NF-κB, p38, and c-Jun N-terminal kinase (JNK). Taken together, our results suggest that IVIG attenuates LPS-induced cytokine production predominantly mediated by its Fc region. The activity might be regulated by inhibiting NF-κB, p38, and JNK pathways in human monocytic cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644107     DOI: 10.1007/s00210-012-0765-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

Review 1.  Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin.

Authors:  C J Rhoades; M A Williams; S M Kelsey; A C Newland
Journal:  Blood Rev       Date:  2000-03       Impact factor: 8.250

Review 2.  Compensatory anti-inflammatory response syndrome.

Authors:  Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

3.  Fb'2, a new peptic fragment of human immunoglobulin G.

Authors:  D M Parr; G E Connell; D I Kells; T Hofmann
Journal:  Biochem J       Date:  1976-04-01       Impact factor: 3.857

Review 4.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 5.  Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors:  Y Abe; A Horiuchi; M Miyake; S Kimura
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

6.  Optimized THP-1 differentiation is required for the detection of responses to weak stimuli.

Authors:  E K Park; H S Jung; H I Yang; M C Yoo; C Kim; K S Kim
Journal:  Inflamm Res       Date:  2007-01       Impact factor: 4.575

7.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Papain hydrolysis products in four M-IgG subclasses.

Authors:  J Snigurowicz; M Powiertowska-Rezmer
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1980       Impact factor: 4.291

9.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

10.  Involvement of mitogen-activated protein kinases and NFkappaB in LPS-induced CD40 expression on human monocytic cells.

Authors:  Weidong Wu; Neil E Alexis; Xian Chen; Philip A Bromberg; David B Peden
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-14       Impact factor: 4.219

View more
  8 in total

1.  Intravenous immunoglobulin preparation prevents the production of pro-inflammatory cytokines by modulating NFκB and MAPKs pathways in the human monocytic THP-1 cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Fujio Kobayashi; Atsushi Nakano; Akihito Kamizono
Journal:  Inflamm Res       Date:  2014-05-29       Impact factor: 4.575

2.  Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia.

Authors:  Ker Zhing Lok; Milan Basta; Silvia Manzanero; Thiruma V Arumugam
Journal:  J Neuroinflammation       Date:  2015-04-15       Impact factor: 8.322

3.  An fc gamma receptor-mediated upregulation of the production of interleukin 10 by intravenous immunoglobulin in bone-marrow-derived mouse dendritic cells stimulated with lipopolysaccharide in vitro.

Authors:  Akihiro Fujii; Yuko Kase; Chiaki Suzuki; Akihito Kamizono; Teruaki Imada
Journal:  J Signal Transduct       Date:  2013-06-18

4.  Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response.

Authors:  Alexandra Richard; Jean-Christophe Corvol; Rabab Debs; Pauline Reach; Khadija Tahiri; Wassila Carpentier; Justine Gueguen; Vincent Guillemot; Céline Labeyrie; David Adams; Karine Viala; Fleur Cohen Aubart
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 5.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

6.  Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

Authors:  Richard J Jones; Ram K Singh; Fazal Shirazi; Jie Wan; Hua Wang; Xiaobin Wang; Min Jin Ha; Muhamed Baljevic; Isere Kuiatse; Richard E Davis; Robert Z Orlowski
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

7.  IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS.

Authors:  Jelka Hartwig; Franziska Sotzny; Sandra Bauer; Harald Heidecke; Gabriela Riemekasten; Duska Dragun; Christian Meisel; Claudia Dames; Patricia Grabowski; Carmen Scheibenbogen
Journal:  Brain Behav Immun Health       Date:  2020-02-05

8.  Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.

Authors:  Andrew R Crow; Honghui Yu; Dongji Han; Alan H Lazarus
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.